Whole Genome Sequencing Market to Be Worth $7.17 Billion by 2031 - Exclusive Report by Meticulous Research®

News provided by

Meticulous Market Research Pvt. Ltd.

Nov 11, 2024, 11:00 ET

REDDING, Calif. , Nov. 11, 2024 /PRNewswire/ -- According to a new market research report titled, 'Whole Genome Sequencing Market Size, Share, Forecast, & Trends Analysis by Offering (Library Preparation, DNA Extraction) Sequencing Type (Large, Small, Phased), Technology (SBS, SMRT, Nanopore, Nanoball) Application, End User – Global Forecast to 2031,' published by Meticulous Research^®.

The whole genome sequencing market is projected to reach $7.17 billion by 2031 at a CAGR of 15.2% from 2024 to 2031.

Whole Genome sequencing is a method for analyzing entire genome. It determines precise order of every base pair in a genome. Whole genome sequencing provides information about protein coding and non-coding regions. With the advent of next generation sequencing whole genome sequencing have become cheaper, faster and powerful. Whole genome sequencing has wide applications including genetic disease research, cancer research, genotyping and epidemiology.

Download FREE PDF Brochure Of Whole Genome Sequencing Market - https://www.meticulousresearch.com/download-sample-report/cp_id=6069

The growth of this market can be attributed the declining costs of sequencing, the increasing prevalence of cancer & genetic disorders, the growing utilization of whole genome sequencing in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for whole genome sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for the early detection & prevention of diseases, technological advancements in sequencing products, and government initiatives promoting the use of sequencing in clinical & research applications. However, the high costs of whole genome sequencing consumables, the low chances of identifying positive actionable mutations for precision medicine, and the ethical & legal issues related to whole genome sequencing-based diagnosis restrain the market's growth.

Furthermore, increasing applications of whole genome sequencing, government support for large-scale genomic sequencing projects, and emerging economies are expected to generate growth opportunities for the players operating in this market. However, uncertainties in the regulatory landscape, the limited expertise & sequencing capabilities of small & medium-sized laboratories, the lack of sequencing professionals in developing countries, and the high capital investments required for NGS setups are major challenges impacting market growth.

Emerging whole genome sequencing companies' focus on improving technologies and reducing costs and key market players' emphasis on portable and real-time sequencing technologies are prominent trends in the whole genome sequencing market.

The Growing Utilization of Whole Genome Sequencing in Disease Diagnostics & Precision Medicine is Driving the Market.

The utilization of sequencing technologies is rapidly growing in precision medicine. Advancements in genome sequencing technologies are changing how doctors diagnose and treat cancer. New targeted cancer treatments that use genomic data to provide patient-specific treatments are known as precision oncology, a rapidly developing field that has already become a part of mainstream clinical practices. It involves the molecular profiling of cancer cells to identify targetable alterations, also known as biomarkers. Quick and reliable simultaneous sequencing of multiple genes has become possible with the availability of sequencing technologies such as NGS and nanopore sequencing.

The advent of NGS has helped develop precision medicine, which involves tailoring treatments based on disease-causing molecular changes in a person's body. While whole genome sequencing is conducted in various scenarios, oncologists are currently using it to sequence patients' biopsy samples to determine the right medicines that can target the genetic abnormalities driving tumor growth.

Get Insightful Data On Regions, Market Segments, Customer Landscape, And Top Companies (Charts, Tables, Figures And More) - https://www.meticulousresearch.com/request-sample-report/cp_id=6069

The key players operating in the whole genome sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S) Agilent Technologies, Inc. (U.S), Pacific Biosciences of California Inc. (U.S), Danaher Corporation (U.S), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K),MGI Tech Co., Ltd. (China), Beijing Genomics Institute (BGI) (China).

Whole Genome Sequencing Industry Overview: Latest Developments from Key Industry Players (INSTANT DOWNLOAD FREE PDF SAMPLE)

In May 2024, QIAGEN N.V. (Netherland) launched QIAseq Multimodal DNA/RNA Library Kit. The kit enables the preparation of RNA and DNA libraries for NGS, which includes whole transcriptome sequencing (WTS) and whole genome sequencing (WGS).
In November 2023, QIAGEN N.V. (Netherland) launched a research workflow that includes high-quality DNA extraction kits, library preparation for whole genome metagenomics, and user-friendly bioinformatics analysis.
In October 2023, Pacific Biosciences of California Inc. (U.S.) launched the Pacific Biosciences of California WGS variant pipeline. It is a complete, standardized computational method for HiFi Whole Genome Sequencing (WGS) data analysis.
In March 2023, Illumina, Inc. (U.S.) launched Connected Insights, a cloud-based software for tertiary analysis of clinical next-generation sequencing data, including somatic oncology applications, whole genome sequencing for rare diseases, and reduced turnaround time of clinical reporting via integration of third-party knowledge bases.
In July 2022, Beijing Genomics Institute (BGI) (China), BGI Genomics partnered with the Serbian Genome Sequencing and Bioinformatics Center to enhance and develop the center's whole exome sequencing (WES), whole genome sequencing (WGS), and genomic analysis capabilities.

Based on offerings studied in this report, in 2024, the consumables segment is slated to register the highest CAGR of 15.4% during the forecast period. Growing demand for whole genome sequencing kits and reagents and increasing whole genome sequencing product launches by key market players. Furthermore, recurring demand for whole genome sequencing consumables, and increase in number of sequencing projects are factors expected to support the segment's high growth.

Based on sequencing types studied in this report in 2024, the large whole-genome sequencing segment is slated to register the highest CAGR of 15.8% during the forecast period. The large whole-genome sequencing helps in identification of causative variants which helps in further studies of regulation mechanism and gene expression, helps in sequencing large genome for providing population level studies which increases the adoption of large whole genome sequencing in research are factors expected to support the segment's high growth.

Based on technologies studied in this report, in 2024, the sequencing by synthesis segment is slated to register the highest CAGR of 16.2% during the forecast period. The sequencing by synthesis technology offers long-insert paired-end reads for de novo sequencing and sequence assembly, it supports both paired end and single read libraries. Furthermore, its cost effectiveness, and high-resolution genome sequencing offered by the technology increases the adoption of the sequencing by synthesis technology are factors expected to support the segment's high growth.

Have Specific Research Needs? Request a Customized Research Report -https://www.meticulousresearch.com/request-customization/cp_id=6069

Based on applications studied in this report, the clinical applications segment is slated to register the highest CAGR of 17.3% during the forecast period. The growing cases of infectious diseases, and rising number of cancer cases. According to the World Health Organization, the global burden of cancer is expected to increase from 19.3 million cases in 2020 to 24.6 million cases by 2030 are factors expected to support the segment's high growth.

Based on end users studied in this report, in 2024, hospitals & Diagnostic Laboratories segment is slated to register the highest CAGR of 16.7% during the forecast period. Hospitals & diagnostic laboratories are dedicated facilities for various diagnostic procedures. These facilities are involved in genetic disease testing, infectious diseases testing, NIPT, carrier screening, in-vitro fertilization, and newborn screening. All these procedures require whole genome sequencing products to obtain critical insights for treatment purposes. The growing adoption of NGS in diagnostic laboratories are factors expected to support the segment's high growth.

This research report analyzes major geographies and provides a comprehensive analysis of the market in North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa.

Among all regions studied in this report, Asia-Pacific is expected to register the highest CAGR of 16.4% during the forecast period. The growth of this segment is attributed to the increasing investments from market players and government organizations in healthcare sector, rising focus on medical tourism and becoming competitive in the global biotech market. Additionally, governments in this region are aiming to make considerable developments in genomic research. For instance, in March 2024, the Genome India Project, started by Department of Biotechnology in India completed sequencing of 10,000 Indian genomes. Also, the bioeconomy of India is expected to grow approximately to USD 130 billion in 2024 from USD 10 billion of 2014.

IMMEDIATE DELIVERY AVAILABLE | BUY THIS RESEARCH REPORT (Insights, Charts, Tables, Figures and More)-
https://www.meticulousresearch.com/Checkout/75638142

Scope of the Report:

Whole Genome Sequencing Market Assessment— by Offering

Consumables
- Sample Preparation Kits & Reagents
  - Nucleic Acid Extraction & Amplification
  - Library Preparation & Target Enrichment
  - Quality Control
- Other Consumables
Instruments
Software
Services

Note: Other consumables include vials, pipettes, containers, trays, sequencing reagents, flow cells, and tubes.

Whole Genome Sequencing Market Assessment— by Sequencing Type

Large Whole-Genome Sequencing
Small Whole-Genome Sequencing
Human Whole-Genome Sequencing
Other Whole-Genome Sequencing Types

Note: Other Whole-genome sequencing types include De novo sequencing, Phased sequencing, Long-read sequencing, Clone-by-clone sequencing.

Whole Genome Sequencing Market Assessment— by Technology

Sequencing by Synthesis
Ion Semiconductor Sequencing
DNA Nanoball Sequencing
Single-molecule Real-time Sequencing
Other NGS Technologies

Note: Other whole genome sequencing technologies include nanopore sequencing and AVITI sequencing (Avidity base chemistry (ABC).

Whole Genome sequencing Market Assessment—by Application

Research and Other Applications

Drug Discovery
Agriculture and Animal Research
Other Applications

Clinical Applications

Reproductive Health
Oncology
Infectious Diseases
Other Clinical Applications

Note: Other applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies.

Other clinical applications include the detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses.

Whole Genome Sequencing Market Assessment—by End User

Pharmaceutical & Biotechnology Companies
Hospitals & Diagnostic Laboratories
Academic Institutes & Research Centers
Other End Users

Note: Other end users primarily include forensic laboratories & security agencies, food & beverage companies, and agriculture companies.

Whole Genome Sequencing Market Assessment—by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe (RoE)
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific (RoAPAC)
Latin America
- Brazil
- Mexico
- Rest of Latin America (RoLATM)
Middle East & Africa

Read More Related Reports:-

Next Generation Sequencing (NGS) Informatics Market is projected to reach $4.3 billion by 2030, at a CAGR of 15.4% from 2023 to 2030 - https://www.meticulousresearch.com/product/ngs-informatics-market-3483

Next Generation Sequencing Services Market is expected to register a CAGR of 19.8% from 2024 to 2031 to reach $24.44 billion by 2031 - https://www.meticulousresearch.com/product/next-generation-sequencing-services-market-5041

Next generation sequencing market is expected to reach $27.5 billion by 2030, at a CAGR of 15.8% from 2023–2030 - https://www.meticulousresearch.com/product/next-generation-sequencing-market-5040

Sequencing Kits Market is projected to reach $25.29 billion by 2031, at a CAGR of 15.5% from 2024 to 2031- https://www.meticulousresearch.com/product/sequencing-kits-market-5656

DNA Sequencing Market, valued at $9.14 Billion in 2023, is projected to reach $21.30 Billion by 2031, growing at a CAGR of 11.8% from 2024 to 2031 - https://www.meticulousresearch.com/product/dna-sequencing-market-5992

NGS Automation Market is expected to grow at a CAGR of 13.4% from 2022–2029 to reach $1.33 billion by 2029 - https://www.meticulousresearch.com/product/ngs-automation-market-5271

Whole Genome Sequencing Market Research Summary -

Particulars	Details
Number of Pages	312
Format	PDF
Forecast Period	2024-2031
Base Year	2023
CAGR	15.2 %
Estimated Market Size (Value)	$7.17 billion by 2031
Segments Covered	by Offering Consumables Sample Preparation Kits & Reagents Nucleic Acid Extraction & Amplification Library Preparation & Target Enrichment Quality Control Other Consumables Other Consumables Instruments Software Services (Note: Other consumables include vials, pipettes, containers, trays, sequencing reagents, flow cells, and tubes.) by Sequencing Type Large Whole-genome Sequencing Small Whole-genome Sequencing Phased Sequencing Other Whole-genome Sequencing Types (Note: Other sequencing types include De novo sequencing, Phased sequencing, Long-read sequencing, Clone-by-clone sequencing.) by Technology Sequencing by Synthesis Ion Semiconductor Sequencing DNA Nanoball Sequencing Single-molecule Real-time Sequencing Other NGS Technologies (Note: Other whole genome sequencing technologies include nanopore sequencing and AVITI sequencing (Avidity base chemistry (ABC).) by Application Research and Other Applications Drug Discovery Agriculture and Animal Research Other Applications Clinical Applications Reproductive Health Oncology Infectious Diseases Other Clinical Applications (Note 1: Other applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies.) (Note 2: Other clinical applications include the detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses.) by End User Pharmaceutical & Biotechnology Companies Hospitals & Diagnostic Laboratories Academic Institutes & Research Centers Other End Users (Note: Other end users primarily include forensic laboratories & security agencies, food & beverage companies, and agriculture companies.)
Countries Covered	North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa
Key Companies	Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S) Agilent Technologies, Inc. (U.S), Pacific Biosciences of California Inc. (U.S), Danaher Corporation (U.S), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K), MGI Tech Co., Ltd. (China), Beijing Genomics Institute (BGI) (China)